Masahiro Matsubara

Summary

Affiliation: Kyowa Hakko Kogyo Co
Country: Japan

Publications

  1. ncbi Differential regulation of IL-4 expression and degranulation by anti-allergic olopatadine in rat basophilic leukemia (RBL-2H3) cells
    Masahiro Matsubara
    Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co, Ltd, 1188 Shimotogari, Nagaizumi cho, Sunto gun, Shizuoka 411 8731, Japan
    Biochem Pharmacol 67:1315-26. 2004
  2. ncbi Histamine H1 receptor-stimulated interleukin 8 and granulocyte macrophage colony-stimulating factor production by bronchial epithelial cells requires extracellular signal-regulated kinase signaling via protein kinase C
    Masahiro Matsubara
    Department of Pharmacology and Molecular Biology, Pharmaceutical Research Center, Kyowa Hakko Kogyo Co, Ltd, Shizuoka, Japan
    Int Arch Allergy Immunol 139:279-93. 2006
  3. ncbi Benidipine, a dihydropyridine-calcium channel blocker, inhibits lysophosphatidylcholine-induced endothelial injury via stimulation of nitric oxide release
    Masahiro Matsubara
    Department of Pharmacology and Molecular Biology, Pharmaceutical Research Center, Kyowa Hakko Kogyo Co, Ltd, Nagaizumi cho, Sunto gun, Shizuoka, Japan
    Pharmacol Res 53:35-43. 2006
  4. ncbi Histamine H1 receptor antagonist blocks histamine-induced proinflammatory cytokine production through inhibition of Ca2+-dependent protein kinase C, Raf/MEK/ERK and IKK/I kappa B/NF-kappa B signal cascades
    Masahiro Matsubara
    Department of Pharmacology and Molecular Biology, Pharmaceutical Research Center, Kyowa Hakko Kogyo Co Ltd, Shizuoka 411 8731, Japan
    Biochem Pharmacol 69:433-49. 2005
  5. ncbi Benidipine, a dihydropyridine-calcium channel blocker, prevents lysophosphatidylcholine-induced injury and reactive oxygen species production in human aortic endothelial cells
    Masahiro Matsubara
    Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co Ltd, 1188 Shimotogari, Nagaizumi cho, Sunto gun, Shizuoka 411 8731, Japan
    Atherosclerosis 178:57-66. 2005
  6. ncbi Effects of benidipine, a dihydropyridine-Ca2+ channel blocker, on expression of cytokine-induced adhesion molecules and chemoattractants in human aortic endothelial cells
    Masahiro Matsubara
    Department of Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co, Ltd, 1188 Shimotogari, Nagaizumi cho, Sunto gun, Shizuoka 411 8731, Japan
    Eur J Pharmacol 498:303-14. 2004
  7. ncbi Staphylococcus aureus peptidoglycan stimulates granulocyte macrophage colony-stimulating factor production from human epidermal keratinocytes via mitogen-activated protein kinases
    Masahiro Matsubara
    Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co, Ltd, 1188 Shimotogari, Nagaizumi cho, Sunto gun, Shizuoka 411 8731, Japan
    FEBS Lett 566:195-200. 2004
  8. ncbi Benidipine, an anti-hypertensive drug, inhibits reactive oxygen species production in polymorphonuclear leukocytes and oxidative stress in salt-loaded stroke-prone spontaneously hypertensive rats
    Masahiro Matsubara
    Pharmaceutical Research Center, Kyowa Hakko Kogyo Co, Ltd, 1188 Shimotogari, Sunto gun, Shizuoka 411 8731, Japan
    Eur J Pharmacol 580:201-13. 2008
  9. ncbi The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family
    Hiromichi Kosaka
    Drug Discovery Research Laboratories, Kyowa Hakko Kirin Co, Ltd, Sunto gun, Shizuoka, Japan
    Eur J Pharmacol 635:49-55. 2010
  10. ncbi Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R
    Osamu Akizuki
    Pharmaceutical Research Center, Kyowa Hakko Kogyo Co, Ltd, Shizuoka 411 8731, Japan
    Eur J Pharmacol 584:424-34. 2008

Collaborators

Detail Information

Publications16

  1. ncbi Differential regulation of IL-4 expression and degranulation by anti-allergic olopatadine in rat basophilic leukemia (RBL-2H3) cells
    Masahiro Matsubara
    Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co, Ltd, 1188 Shimotogari, Nagaizumi cho, Sunto gun, Shizuoka 411 8731, Japan
    Biochem Pharmacol 67:1315-26. 2004
    ....
  2. ncbi Histamine H1 receptor-stimulated interleukin 8 and granulocyte macrophage colony-stimulating factor production by bronchial epithelial cells requires extracellular signal-regulated kinase signaling via protein kinase C
    Masahiro Matsubara
    Department of Pharmacology and Molecular Biology, Pharmaceutical Research Center, Kyowa Hakko Kogyo Co, Ltd, Shizuoka, Japan
    Int Arch Allergy Immunol 139:279-93. 2006
    ..However, the functional individual histamine receptor subtype and intracellular signaling in bronchial epithelial cells are poorly defined...
  3. ncbi Benidipine, a dihydropyridine-calcium channel blocker, inhibits lysophosphatidylcholine-induced endothelial injury via stimulation of nitric oxide release
    Masahiro Matsubara
    Department of Pharmacology and Molecular Biology, Pharmaceutical Research Center, Kyowa Hakko Kogyo Co, Ltd, Nagaizumi cho, Sunto gun, Shizuoka, Japan
    Pharmacol Res 53:35-43. 2006
    ..The direct enhancement of endothelial NO release by benidipine may be in part responsible for amelioration of endothelial dysfunction...
  4. ncbi Histamine H1 receptor antagonist blocks histamine-induced proinflammatory cytokine production through inhibition of Ca2+-dependent protein kinase C, Raf/MEK/ERK and IKK/I kappa B/NF-kappa B signal cascades
    Masahiro Matsubara
    Department of Pharmacology and Molecular Biology, Pharmaceutical Research Center, Kyowa Hakko Kogyo Co Ltd, Shizuoka 411 8731, Japan
    Biochem Pharmacol 69:433-49. 2005
    ..Thus, the anti-inflammatory benefit of H1 antagonists may be in part due to prevention of cytokine production...
  5. ncbi Benidipine, a dihydropyridine-calcium channel blocker, prevents lysophosphatidylcholine-induced injury and reactive oxygen species production in human aortic endothelial cells
    Masahiro Matsubara
    Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co Ltd, 1188 Shimotogari, Nagaizumi cho, Sunto gun, Shizuoka 411 8731, Japan
    Atherosclerosis 178:57-66. 2005
    ....
  6. ncbi Effects of benidipine, a dihydropyridine-Ca2+ channel blocker, on expression of cytokine-induced adhesion molecules and chemoattractants in human aortic endothelial cells
    Masahiro Matsubara
    Department of Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co, Ltd, 1188 Shimotogari, Nagaizumi cho, Sunto gun, Shizuoka 411 8731, Japan
    Eur J Pharmacol 498:303-14. 2004
    ..Benidipine may thus have anti-inflammatory properties and benefits for in the treatment of atherosclerosis...
  7. ncbi Staphylococcus aureus peptidoglycan stimulates granulocyte macrophage colony-stimulating factor production from human epidermal keratinocytes via mitogen-activated protein kinases
    Masahiro Matsubara
    Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co, Ltd, 1188 Shimotogari, Nagaizumi cho, Sunto gun, Shizuoka 411 8731, Japan
    FEBS Lett 566:195-200. 2004
    ..These results suggested that PGN of S. aureus directly exacerbates inflammation of inflammatory skin disease...
  8. ncbi Benidipine, an anti-hypertensive drug, inhibits reactive oxygen species production in polymorphonuclear leukocytes and oxidative stress in salt-loaded stroke-prone spontaneously hypertensive rats
    Masahiro Matsubara
    Pharmaceutical Research Center, Kyowa Hakko Kogyo Co, Ltd, 1188 Shimotogari, Sunto gun, Shizuoka 411 8731, Japan
    Eur J Pharmacol 580:201-13. 2008
    ..The attenuation of reactive oxygen species production might contribute to the drug's reduction of oxidative stress and renal injuries in hypertension...
  9. ncbi The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family
    Hiromichi Kosaka
    Drug Discovery Research Laboratories, Kyowa Hakko Kirin Co, Ltd, Sunto gun, Shizuoka, Japan
    Eur J Pharmacol 635:49-55. 2010
    ..These results suggested that benidipine directly inhibits aldosterone-induced mineralocorticoid receptor activation, and the antagonistic activity might contribute to the drug's pleiotropic pharmacological features...
  10. ncbi Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R
    Osamu Akizuki
    Pharmaceutical Research Center, Kyowa Hakko Kogyo Co, Ltd, Shizuoka 411 8731, Japan
    Eur J Pharmacol 584:424-34. 2008
    ..T-type Ca2+ channels may contribute to additional benefits of this drug for treating renal and cardiovascular diseases, beyond its primary anti-hypertensive effects from blocking L-type Ca2+ channels...
  11. ncbi Comparison of the antiatherosclerotic effects of dihydropyridine calcium channel blocker and HMG-CoA reductase inhibitor on hypercholesterolemic rabbits
    Makoto Takayama
    Department of Pharmacology and Molecular Biology, Pharmaceutical Research Center, Kyowa Hakko Kogyo Co, Ltd, 1188 Shimotogari, Nagaizumi cho, Sunto gun, Shizuoka ken, 411 8731, Japan
    Vascul Pharmacol 46:302-8. 2007
    ..Benidipine is effective in preventing vascular hyperplasia without altering serum cholesterol levels and this may be due to inhibition of expression of VCAM-1...
  12. ncbi Effects of benidipine in a rat model for experimental angina
    Jun ichi Ikeda
    Department of Pharmacology and Molecular Biology, Pharmaceutical Research Center, Kyowa Hakko Kogyo Co, Ltd, Shizuoka, Japan
    Yakugaku Zasshi 126:1377-81. 2006
    ....
  13. ncbi Effects of benidipine, a long-lasting dihydropyridine-Ca2+ channel blocker, on cerebral blood flow autoregulation in spontaneously hypertensive rats
    Jun ichi Ikeda
    Department of Pharmacology and Molecular Biology, Pharmaceutical Research Center, Kyowa Hakko Kogyo Co, Ltd, Shizuoka, Japan
    Biol Pharm Bull 29:2222-5. 2006
    ..These results suggest that benidipine may be useful for the treatment of hypertensive patients with the elderly or cerebrovascular disorders, in whom autoregulation of CBF is impaired...
  14. ncbi Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug
    Kenji Ohmori
    Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co, Ltd, Shizuoka, Japan
    Arzneimittelforschung 54:809-29. 2004
    ....
  15. ncbi Mechanism underlying the block of human Cav3.2 T-type Ca2+ channels by benidipine, a dihydropyridine Ca2+ channel blocker
    Atsushi Inayoshi
    Toxicological Research Laboratories, Research Division, Kyowa Hakko Kirin Co, Ltd, Shizuoka 411 8731, Japan
    Life Sci 88:898-907. 2011
    ..In this study, we characterized the mechanism responsible for this blocking activity. Furthermore, the blocking activity was compared between two enantiomers of benidipine, (S, S)- and (R, R)-benidipine...
  16. ncbi Olopatadine ameliorates rat experimental cutaneous inflammation by improving skin barrier function
    Tadafumi Tamura
    Pharmaceutical Research Center, Kyowa Hakko Kogyo Co, Ltd, Shizuoka, Japan
    Pharmacology 81:118-26. 2008
    ..These results suggest that olopatadine suppressed inflammation and scratching not only by inhibiting cytokine production, but also by repairing skin barrier function...